BioNTech carries a favorable risk/reward geometry — 22.6% upside to the analyst-consensus target against 6.5% of measured downside — but that asymmetry sits on top of four consecutive earnings misses, a 35% revenue decline, negative free cash flow, and a quality score well below the minimum threshold; the setup is speculative and the fundamental case requires a clear reversal before conviction is warranted.
Thesis pillars
- Cash Burn Negative Rule Of 40→Stable
- Four Quarter Earnings Miss Streak↑Improving
- Revenue Declining 35 Percent→Stable
- +1 more pillar — see the Why tab for full reasoning
BioNTech SE (BNTX) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $93.09: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 3.0:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 2.20; Below-average business quality; Below long-term trend.
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial,... Read more
Sell if holding. Engine safety override at $93.09: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 3.0:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 2.20; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 57. Score 5.0/10, moderate confidence.
Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 78d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: speculative.
Recent developments
updated 2026-08-16Recent Developments — BioNTech SE
Latest news
- NEWS Trump Says Administration Recognizing Childhood Vaccine Recommendations For Only 11 Core Vaccinations; Hepatitis B, COVI — benzinga Aug 10, 2026 negative
- NEWS Citigroup Maintains Buy on BioNTech, Lowers Price Target to $125 — benzinga Aug 5, 2026 neutral
- NEWS Evercore ISI Group Maintains Outperform on BioNTech, Lowers Price Target to $130 — benzinga Aug 5, 2026 positive
- NEWS BioNTech Lowers FY2026 Sales Guidance from $2.328B-$2.678B to $1.860B-$2.209B vs $2.500B Est — benzinga Aug 4, 2026 negative
- NEWS BioNTech Q2 Adj. EPS $(2.58) Misses $(2.34) Estimate, Sales $122.766M Miss $182.020M Estimate — benzinga Aug 4, 2026 negative
Generated 2026-08-16T17:12:03Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Unprofitable operations — net margin -63.6%. Quality floor flags this regardless of sector context.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $93.09: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 3.0:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 2.20; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 57. Prior stop was $87.95. Score 5.0/10, moderate confidence.
Take-profit target: $108.59 (+16.7% upside). Prior stop was $87.95. Stop-loss: $87.95.
Quality below floor (3.4 < 4.0).
BioNTech SE trades at a P/E of N/A (forward -16.6). TrendMatrix value score: 6.2/10. Verdict: Sell.
28 analysts cover BNTX with a consensus score of 4.0/5. Average price target: $121.
What does BioNTech SE do?BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in...
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.